T1	Participants 433 473	patients with group III rhabdomyosarcoma
T2	Participants 599 742	444 group III patients who received induction therapy, had response assessed at week 8 by anatomic imaging, and continued with protocol therapy
T3	Participants 1786 1804	group III patients
